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of 166 pmol/L p=0·41 vs placebo).8 Why all treated 
participants did not have increases in these hormones 
is unclear, but it must be remembered that if there is 
β-cell sparing in the responsive group, there must be 
a concomitant acceleration of β-cell loss in the non-
responsive group. 
As such, it remains plausible that some treatments 
that modify hormone concentrations might increase the 
resilience and expansion of β cells, and might have a role 
in stabilisation or remission of type 1 diabetes. Although 
DPP-4 inhibitors and GLP1-receptor agonists could be 
viewed as β-cell protective, they also increase the rate 
of insulin release. Of interest, this rationale might be 
contrary to the concept that those with newly diagnosed 
type 1 diabetes have injured β cells and would beneﬁ t 
from so-called β-cell rest via intensive glycaemic control; 
however, there is ongoing debate and conﬂ icting data 
regarding this concept.9,10 
Although non-immune-based treatments sound 
attractive for type 1 diabetes because they have few 
side-eﬀ ects and might be supported by preclinical 
models, we are at a time when the data to move the 
ﬁ eld forward must come from more detailed study of 
type 1 diabetes in human beings. Future studies should 
take into consideration the ﬁ ndings of intervention 
trials of past decades, including negative trials such 
as REPAIR-T1D. From these studies, it is now seems 
evident that type 1 diabetes in human beings is a very 
robust autoimmune disease, for which potent immune-
based treatment (alone or perhaps in combination 
with non-immune-based therapies) will be needed to 
arrest or slow β-cell loss.3 The possibility also remains 
that other interventions (such as those s tudied in 
REPAIR-T1D) could augment that eﬀ ect. However, 
before the autoimmune process of type 1 diabetes is 
controlled, other drugs that do not have proven direct 
immunomodulatory eﬀ ects in human beings probably 
have low prospect of success for this disease. 
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Low vitamin D and hypertension: a causal association?
In The Lancet Diabetes & Endocrinology, Karani 
Vimaleswaran and colleagues1 report the results of 
a mendelian randomisation study with data from 
up to 146 581 individuals, which suggest that low 
vitamin D concentrations might be causally associated 
with an increased risk of hypertension. The investigators 
used variants of genes that aﬀ ect 25-hydroxyvitamin D 
(25[OH]D) synthesis or substrate availability (CYP2R1 
and DHCR7) and report that each 10% increase in 
genetically instrumented plasma 25(OH)D concentration 
was associated with a decrease in diastolic blood pressure 
(−0·29 mm Hg, 95%CI −0·52 to –0·07; p=0·01) and 
systolic blood pressure (−0·37 mm Hg, –0·73 to 0·003; 
p=0·052), and an 8·1% reduced odds of hypertension 
(odds ratio [OR] 0·92, 95% CI 0·87–0·97; p=0·002). 
This study is timely, because a discrepancy exists 
between ﬁ ndings from observational studies and 
results of randomised intervention trials with respect 
to the relation between low vitamin D concentrations 
and increased risk of hypertension, with observational 
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ﬁ ndings suggesting a strong association and trial results 
showing no or only small eﬀ ects. 2,3 Weaknesses inherent 
in observational studies such as reverse causation 
are a possible explanation for this diﬀ erence—eg, 
individuals with hypertension might have more chronic 
diseases and therefore spend less time outdoors with 
sun exposure, important for endogenous vitamin D 
production. Another weakness is confounding; for 
example, obesity might account for the association 
between low vitamin D status and hypertension, because 
individuals with high BMIs have both low vitamin D 
concentration s4,5 and an increased risk of hypertensio n.6 
The mendelian randomisation approach used by 
Vimaleswaran and colleagues1 circumvents reverse 
causation and largely excludes confoundi ng.7,8 This 
approach takes advantage of the random assortment of 
genetic variants that occurs during gamete formation, 
which secures an equal distribution of confounding 
factors among diﬀ erent genotypes. It can therefore be 
used to assess whether genetically aﬀ ected risk factors 
are causally related to clinical outcomes. Thus, this 
design has similarities to a randomised intervention 
trial. Furthermore, genetic variants, like randomisation 
in a clinical trial, cannot be aﬀ ected by diseases later in 
life and are therefore not prone to reverse causation. 
Thus, genetic variants that speciﬁ cally decrease plasma 
25(OH)D concentration (which is generally used to 
assess vitamin D status) can be used to assess the 
consequences of lifelong low 25(OH)D concentrations 
independent of other risk factors. 
Vimaleswaran and colleagues’ results have some 
limitations, however. First, since some of the reported 
p values are close to 0·05, the possibility that their 
ﬁ ndings are the result of chance cannot be excluded. 
Second, 25(OH)D-increasing genetic variants were 
associated with reduced hypertension as a binary 
outcome (OR per allele, 0·98, 95% CI 0·96–0·99; 
p=0·001), but only borderline associated with 
blood pressure on a continuous scale (–0·10 mm Hg 
[–0·21 to –0·0001; p=0·0498] for systolic blood pressure; 
–0·08 mm Hg [–0·15 to –0·02; p=0·01] for diastolic 
blood pressure), which is peculiar since the statistical 
power is typically higher for continuous than for 
dichotomised outcomes. Third, to be clinically relevant, 
25(OH)D-increasing genetic variants should be causally 
associated with reduced risk of hypertension as well as 
with stroke, but the risk of stroke was not examined in 
the study. Finally, pleotropic eﬀ ects represent a potential 
limitation in genetic studies—ie, genotypes might aﬀ ect 
hypertension via a mechanism not directly related to low 
25(OH)D concentrations—and such pleotropic eﬀ ects 
are diﬃ  cult to rule out completely.
Randomised intervention trials are the gold standard 
to help establish causality, and must show a beneﬁ t 
before widespread vitamin D supplementation can 
be recommended for prevention or treatment of 
hypertension. However, with respect to understanding 
causality, the mendelian randomisation approach 
has two important diﬀ erences from randomised 
intervention trials. First, the use of genetic variants 
that aﬀ ect plasma 25(OH)D concentrations might 
capture the variation caused by one or more of the three 
potential sources of vitamin D (sun exposure, diet, and 
supplements), rather than the eﬀ ect of supplements 
only, as assessed in randomised trials. Second, genetic 
studies examine lifelong exposure to 25(OH)D 
concentrations, rather than time-limited interventions. 
Thus, estimates from randomised intervention trials 
might be somewhat attenuated compared with 
estimates from mendelian randomisation studies. 
Although Vimaleswaran and colleagues’ study is 
an important step towards delineation of the role of 
low vitamin D concentrations in the pathogenesis of 
hypertension, much remains unknown. Conﬁ rmation of 
these results in independent, similarly powered studies 
will be necessary, as will evidence of a corresponding 
beneﬁ t for the prevention of diseases caused by 
hypertension such as stroke. Finally, randomised 
intervention trials will be needed to determine whether 
vitamin D supplementation can be used to prevent or 
treat hypertension before such a strategy can be used 
clinically.
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Two novel antihyperglycaemic drug classes for the 
treatment of type 2 diabetes might have important, 
clinically relevant oﬀ -target eﬀ ects. The so-called incretin-
based drugs—ie, glucagon-like peptide-1 (GLP-1) receptor 
agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors—
mainly reduce glucose con centration by improving 
pancreatic islet-cell function.1 However, ﬁ ndings from 
clinical trials and preclinical studies suggest that incretin-
based drugs have extra-pancreatic actions that interact 
with the renin-angiotensin-aldosterone system (RAAS; 
ﬁ gure),1 inhibitors of which are antihypertensive drugs 
taken daily by patients with type 2 diabetes. 
Evidence from model systems1,2 suggests that GLP-1 
receptor activation inhibits intracellular signalling of 
the angiotensin II type 1 receptor, which mediates 
harmful eﬀ ects of RAAS—such as inﬂ ammation and 
hypertension.1,2 In healthy people, acute GLP-1 infusion 
lowers circulating angiotensin II concentrations by 
15–19% and leads to a non-signiﬁ cant reduction in 
plasma renin activity.2,3 In one study that included obese 
patients with glomerular hyperﬁ ltration,3 25% of whom 
had type 2 diabetes, GLP-1 infusion reduced plasma renin 
activity by 25% (ﬁ gure). The reduced renin secretion 
might be accounted for by a direct eﬀ ect of GLP-1 on 
the juxtaglomerular cells,4 via atrial natriuretic peptide,1 
or through inhibition of tubuloglomerular feedback by 
inhibition of proximal sodium reabsorption.1,2 Skov and 
colleagues2 hypothesised that many GLP-1-mediated 
eﬀ ects on RAAS—including glucose-dependent insulin 
secretion, renoprotection, and inhibition of the Na+/H+ 
exchanger isoform 3 in the proximal tubule—are partly 
caused by decreased angiotensin-II signalling. Stronger 
inhibition of the RAAS cascade by GLP-1 receptor 
agonists might further increase the protective eﬀ ects 
of compounds that interact with RAAS. However, the 
clinical beneﬁ t of such augmented inhibition could be 
questionable in view of the results of the ONTARGET, 
ALTITUDE, and the recently stopped VA NEPHRON-D 
trials, which showed increased risk of adverse events, 
including hyperkalaemia and renal failure, when two 
diﬀ erent drugs that synergistically inhibit RAAS were 
combined.5 As a result, dual RAAS blockade in patients 
with diabetes is currently not recommended.5 Notably, 
Figure: Proposed interactions of incretin-based drugs with RAAS and the pharmacological compounds that 
interact with RAAS
(A) Glucagon-like peptide-1 (GLP-1) might decrease circulating concentrations of angiotensin II, directly or 
through inhibition of renin production or release, in addition to inhibiting angiotensin II type 1 receptor 
(AT1-R) after receptor activation (inhibition of ERK1 [MAPK3] and ERK2 [MAPK1] phosphorylation and NF-κB 
activation). (B) Dipeptidyl peptidase-4 (DPP-4) is the main cause of the inactivation of substance P when 
angiotensin-converting enzyme (ACE) is inhibited. Increased concentrations of active substance P during 
combined pharmacological inhibition might raise sympathetic activity, thereby increasing vascular tone and 
heart rate. Decreased DPP-4-mediated degradation of neuropeptide Y (NPY) might augment the vascular 
eﬀ ect. RAAS=renin-angiotensin-aldosterone system.
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